Catalog Products » CD37 hFc Chimera, Human
Manual
Manual
COAs

CD37 hFc Chimera, Human

CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients.
$340.00
Z04199-100

Ask us a question
Product Introduction
Species Human
Protein Construction
hFc CD37 (Ala113-Asn240)
Accession # P11049-1
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 41.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

CD37 HFc Chimera, Human

The purity of CD37 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

CD37 HFc Chimera, Human

CD37 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients.
Synonyms Tetraspanin-26; Tspan-26; CD37; CD37 molecule; GP52-40; MGC120234
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.